Relating to access to individualized investigational treatments for patients with life-threatening or severely debilitating illnesses.

HB 3318 creates a framework for patients with life-threatening or severely debilitating illnesses to access personalized investigational treatments (like gene therapies or vaccines tailored to their genetic makeup) when standard FDA-approved options have been exhausted. It requires patients to have written consent, a physician's attestation confirming their condition and eligibility, and documentation that all other approved treatments were considered. Healthcare facilities must already comply with federal human subjects protections to provide these treatments. The bill directly affects patients with serious illnesses, their physicians, and qualifying medical facilities, without altering insurance coverage or creating new funding.